Suzhou Suncadia Biopharmaceuticals

CompanyChina

Suzhou Suncadia Biopharmaceuticals develops 2 assets, the furthest in phase 2 (adebrelimab in locally advanced resectable rectal cancer). Mostly antibody acting on CD274 and CD73; based in China.

Assets
2
Furthest
Phase 2
Trials
10
Signals
0

Pipeline

2

  • adebrelimab

    Humanized monoclonal antibody targeting PD-L1 to reverse immune suppression.

    Phase 2AntibodyCD274locally advanced resectable rectal cancer

  • SHR-8068

    Monoclonal antibody targeting CD73 (NT5E) to inhibit adenosine-mediated immunosuppression.

    Phase 2AntibodyCD73locally advanced resectable rectal cancer

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms2
  • Trials12
  • Signals3
  • Similar companies6

Updated 7 Oct 2026 · 17 sources

Intelligence